Stock AnalizINSMED Inc INSM
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
INSMED Inc (INSM) is a healthcare company listed in the US with a market value of about $26.6B. In the twelve months to September 30, 2026 it had revenue of $1.5B and net income of -$606M, a net margin of -39.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 30% a year, a 5-year average ROIC of -50%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $606M | $364M | $305M | $245M | $188M | $164M | $136M | $10M | $0 | $0 |
| Net income | -$606M | -$1.3B | -$914M | -$750M | -$482M | -$435M | -$294M | -$254M | -$324M | -$193M | -$176M |
| Free cash flow | -$628M | -$968M | -$706M | -$550M | -$410M | -$371M | -$226M | -$293M | -$271M | -$163M | -$151M |
| EPS (diluted) | $-2.81 | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | $-4.22 | $-2.89 | $-2.85 |
| Net margin | -39.9% | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% | -3297.2% | — | — |
| ROIC | — | -75.3% | -48.7% | -64.8% | -28.6% | -30.1% | -27.6% | -24.7% | -36.9% | -45.3% | -65.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 22 analysts is $194.18, 60% above the current price; targets range from $158.00 to $243.00; the consensus rating is “Strong buy”; expected EPS is $-1.67 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does INSMED pay a dividend?
Not currently.
Is INSMED a good stock to buy?
We do not give buy or sell advice. INSMED scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.